Companies and laboratories

Exiris is a Biotech founded in 2010 by a group of former Merck & Co. scientists that uses a unique combination of technology platforms to discover novel oncology targets and to generate innovative biological therapeutic agents for the treatment of indications with high unmet medical need. Exiris has decades of experience, obtained during many years of successful translational research at Merck & Co, in generating preclinical pharmacology data to guide clinical development to Go/No Go decisions. Exiris has also developed a proprietary antibody phage library and platform technologies for conjugation of antibodies, peptides and small molecules to cytotoxic agents, develops its products up to preclinical proof of concept and seeks partnerships for clinical development. Exiris also provides expertise and experimental platforms on a fee-for-service basis, is open to co-development deals and actively pursues in-licensing and internal development of highly innovative agents.